The phase 2 SABINA trial (NCT05810870) investigated MEN1611 (a phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha [PIK3CA] inhibitor) alone and in combination with eribulin in HR+/HER2-negative metastatic BC-Mp patients with alterations in PIK3CA or phosphatase and tensin homolog (PTEN), assessing both its safety and efficacy. The gene discussed is ERBB2; the disease is breast cancer.